All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Ongoing | 2014-001263-12 | Crizotinib in pretreated metastatic non-small-cell lung cancer with MET amplification or ROS1 translocation (METROS) Crizotinib nel tumore pretrattato al polmone non a piccole cellule con amplifica... | not-yet-due | |
Ongoing | 2016-001259-34 | PF-06463922 for crizotinib pretreated ROS1 positive non-small-cell lung cancer: a phase II Trial (PFROST) PF-06463922 nel tumore al polmone non a piccole cellule con traslocazione ROS1 pretrattat... | not-yet-due | |
Ongoing | 2016-004003-31 | SQUINT (Squamous Immunotherapy Nivolumab-Ipilimumab Trial): An open-label, randomized, phase II trial of Nivolumab plus Ipilimumab versus platinum-based chemotherapy in chemonaive metastatic or recurr... | not-yet-due | |
Ongoing | 2017-003509-16 | Serum cytokine levels as predictors of the efficacy of aflibercept in combination with FOLFIRI in metastatic Colo-Rectal Cancer patients (mCRC) Livelli sierici di citochine come predittori di effic... | not-yet-due | |
Ongoing | 2017-004157-16 | Phase II single arm study with CABozantinib in Non-Small Cell Lung Cancer patients with MET deregulation Studio di fase II a singolo braccio con cabozantinib in pazienti con carcinoma polmonare non... | not-yet-due | |
Ongoing | 2018-003645-41 | Phase II trial evaluating the efficacy of durvalumab (MEDI4736) as second-line therapy in Non- Small-Cell Lung Cancer patients receiving concomitant steroids Studio di fase II che mira a valutare l... | not-yet-due | |
Ongoing | 2018-003973-82 | Phase II randomized trial comparing atezolizumab versus atezolizumab plus bevacizumab as first-line treatment in PD-L1 high advanced non-small-cell lung cancer patients Studio randomizzato di fase... | not-yet-due | |
Ongoing | 2019-002869-35 | A randomized, non-comparative, phase II study investigating the best epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) sequence in advanced or metastatic non-small-cell lung cancer... | not-yet-due | |
Exempt Terminated | 2019-004070-26 | A Phase 1/2 Study Exploring Safety, Tolerability and Efficacy of BRIgatinib in Combination With CEtuximab in Subjects With Advanced EGFR mutated or ALK or ROS1 positive Non-Small Cell Lung Cancer and ... | 2023-05-05 | not-yet-due |
Ongoing | 2020-005170-10 | A multicenter, Phase II, open label, randomized trial evaluating the efficacy of Tedopi plus docetaxel or Tedopi plus nivolumab as second-line therapy in metastatic non-small-cell lung cancer progress... | not-yet-due | |
Completed, but no date Terminated | 2020-005890-29 | Comparative efficacy of therapeutic strategies for at home early treatment of mild or moderate COVID-19 patients on the reduction of the risk of disease worsening: A multi-stage multi-arm adaptive ran... | bad-data | |
Ongoing | 2021-001713-37 | Phase II, two-cohorts, randomized trial comparing standard of care versus immune-based combination in relapsed stage III non-small-cell lung cancer (NSCLC) pretreated with chemoradiotherapy and durval... | not-yet-due |